About the journal
MedComm – Oncology is an open-access journal published by Wiley in Australia, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 2,600 USD. Declared review time at DOAJ: 15 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Wiley
- ISSN
- 2769-6448
- Country
- Australia
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,600 USD
- Articles in DOAJ
- 157
- Declared review time
- 15 weeks
- Declared peer-review model
- peer_review
- Official website
- https://onlinelibrary.wiley.com/journal/27696448
Index listings
- DOAJ · 2023-05-11
- Indexing
- DOAJ
- APC
- 2,600 USD
- Declared review time (DOAJ)
- 15 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
157
Most recent article
4 months ago
Average review time (journal-declared via DOAJ)
15weeks
Works in OpenAlex
192
Last recorded publication year
2026
h-index
19
i10-index
29
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-03-17
- Added to DOAJ
- 2023-05-11
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 84%
- ORCID iDs in current deposits
- 79%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9918822487306676
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
- Cancer Cells and Metastasis
Show all subjects (50)
- Nanoplatforms for cancer theranostics
- Cancer Research and Treatments
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Immune cells in cancer
- Cancer-related molecular mechanisms research
- Immune cells in cancer
- CAR-T cell therapy research
- Human auditory perception and evaluation
- Educational Robotics and Engineering
- Diverse Scientific and Economic Studies
- Human auditory perception and evaluation
- Diverse Scientific and Economic Studies
- Educational Robotics and Engineering
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- Cancer Genomics and Diagnostics
- Circular RNAs in diseases
- MicroRNA in disease regulation
- Circular RNAs in diseases
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Endoplasmic Reticulum Stress and Disease
- Cancer, Lipids, and Metabolism
- Social Media in Health Education
- Social Media in Health Education
- RNA Interference and Gene Delivery
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Endoplasmic Reticulum Stress and Disease
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Nanoparticle-Based Drug Delivery
Keywords (DOAJ)
- cancer
- gene therapy
- cancer metabolism
- immunotherapy
- cancer biomarkers
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ